Airway Complication of Anesthesia
Conditions
Keywords
Supraglottic airway device, LMA Protector
Brief summary
The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice.
Detailed description
There is a lack of research data on regarding the use of the LMA Protector. There is no regulatory requirement to collect or publish patient data on any device, either before CE marking or after. These devices are freely purchased and used. There is, however, a professional duty to know that a device conforms to established norms for use. These norms are not official standards but rather, reference data against which a device can be clinically judged. Therefore, a device that is easy to insert but has a low 'leak pressure' (see above) is different from one that is more difficult to insert but as a high leak pressure. It is not that one is 'better' than the other, but rather that the data help create a 'usability profile' of the device which can be useful when making a clinical selection for the device. Preoperative assessment: During the preoperative visit, patient information leaflet will be given to the patients meeting the eligibility criteria. Wherever possible, suitable patients will be identified in the preoperative assessment clinic and the information leaflet given. The patients will be given adequate time to read this information and any queries will be answered before being asked to sign a consent form. A detailed airway assessment will be performed by one of the investigators and documented on the study proforma. Induction of anaesthesia: On arrival in the anaesthetic room patients will be monitored with pulse oximetry, electrocardiography and invasive or non-invasive blood pressure measurements. After intravenous access is secured and the pre-surgical checklist completed, all patients will be pre-oxygenated using a facemask to achieve end tidal oxygen concentration of at least 80%. A 'sniffing' position of the head and neck and a 20 degree head-up bed tilt will be used for pre-oxygenation. General anaesthesia will be induced intravenously. After induction of anaesthesia, facemask ventilation will be commenced and anaesthesia maintained with an inhalational anaesthetic agent in oxygen or with total intravenous anaesthesia. The volatile agent's (anesthetic gases) concentration of 1 MAC adjusted for the patient's age will be achieved and maintained. This is normal process of anaesthesia applicable for all patients irrespective of participation in the study. Supraglottic airway device (SAD) insertion: Once deep plane of anaesthesia is confirmed, with the absence of movement to jaw thrust stimulation the SAD (LMA protector) will be inserted. The size of the device will be based on the manufacturer's recommendations for the body weight. The breathing system will be connected to the device. Ventilation of the lungs will be then confirmed by observing adequate bilateral chest inflation and square end-tidal capnogram wave with positive pressure ventilation. Adequate ventilation will be recorded if three tests are passed: 1) adequate chest movement, 2) an expired tidal volume of at least 7 ml/kg and 3) stable oxygenation. Time would continue until LMA® ProtectorTM inserted successfully. If it is not possible to insert the device or ventilate through it, two more attempts at placement of the device will be allowed. If placement has failed after two further attempts, the study will be abandoned and the other device will be used. If this fails on first attempt a different LMA or tracheal tube will be used as appropriate. Maintenance of anaesthesia and recovery The main interventions refer to the insertion of the airway device into the patient to obtain a airway and allow the conduct of the anaesthetic and therefore the surgery. However, if there are problems with the device and the airway obtained is suboptimal then the below interventions are allowed (which will be noted in the data collection form): 1. Neck extension - move patient's neck upward 2. Neck flexion - move patient's neck downward 3. Chin lift - manoeuvre to open the airway 4. Jaw thrust - manoeuvre to open the airway 5. Reposition of the device At the end of operation, anaesthetic agents will be discontinued while the device is left in place. The device will be removed after the patient has regained consciousness, and has responded to verbal command to open the mouth. Any complications that occur during the use of the device will be recorded. Postoperative assessment Postoperatively in recovery or on the ward, the investigators will visit each patient and determine whether the following airway complications are present after surgery: sore throat (constant pain, independent of swallowing), dysphagia (difficulty in, or pain provoked by, swallowing), sore jaw, dysphonia (difficulty in, or pain on, speaking), numbness of the tongue or the oropharynx, ear pain, neck or mouth ache, hearing changes. Each complication will be graded as none, mild, moderate or severe. The same questions will be asked 24-48 hours later. First visit During the first visit by the anaesthetist to the participant, at the anaesthetist's earliest opportunity, either in the recovery area or on the ward, the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe. 1. Vomiting 2. Lip or tongue swelling 3. Hearing changes 4. Ear pain 5. Sore throat 6. Pain on swallowing 7. Jaw pain 8. Neck or mouth ache 9. Pain on speaking 10. Numbness of the tongue Second visit (or telephone consultation) During the second visit 24-48 hours post-operatively on the ward or via telephone the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe. 1. Vomiting 2. Lip or tongue swelling 3. Hearing changes 4. Ear pain 5. Sore throat 6. Pain on swallowing 7. Jaw pain 8. Neck or mouth ache 9. Pain on speaking 10. Numbness of the tongue
Interventions
The LMA Protector will be inserted when a supraglottic device is needed
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult participants who are having a general anaesthetic. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * ASA 1 - 3 category patients * Elective operations * Urgent operations * Patients suitable for an SAD based on patient and operation factors.
Exclusion criteria
The participant may not enter the study if ANY of the following apply: * Refusal of consent * Age less than 18 years * Require intubation for the operation * Risk of regurgitation * ASA 4 and above * Mouth opening less than 2.5cm Require awake intubation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| First go Insertion Success Rate | Day 1 | Whether insertion during first go was successful or not |
| First go Successful Ventilation Rate | Day 1 | Whether ventilation during first go was successful or not |
| Number of Participants With Complication Free Insertions | Day 1 | Number of participants with complication free insertions divided by total number of participants |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Visible Chest Movement | Day 1 | The success of ventilation will depend on whether there was visible chest movement |
| Number of Participants With Adequate Tidal Volume at Attempt of Ventilation | Day 1 | The success of ventilation will depend on whether there was tidal volume \> 7ml/kg |
| Time to First Square Capnography Waveform | Day 1 | Record time in seconds of time to first capnography trace |
| Number of Participants With Square Capnography Trace | Day 1 | The success of ventilation will depend on whether there was square capnography trace |
| Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Day 1 | Collect number of pre-defined complications of device usage |
| Number of Participants With Stable Oxygen Saturations | Day 1 | The success of ventilation will depend on whether there was stable SpO2 |
| Lowest Oxygen Saturation Level | Day 1 | Record of lowest oxygen saturation reading across all participants |
| Interventions Needed to Ensure Airway Patency | Day 1 | Collect number of predefined interventions needed to keep airway patent |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LMA Protector The LMA Protector will be used
LMA Protector: The LMA Protector will be inserted when a supraglottic device is needed | 111 |
| Total | 111 |
Baseline characteristics
| Characteristic | LMA Protector | — |
|---|---|---|
| Age, Continuous | 68 years | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment Ireland | 61 Participants | — |
| Region of Enrollment United Kingdom | 50 Participants | — |
| Sex: Female, Male Female | 58 Participants | — |
| Sex: Female, Male Male | 53 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 111 |
| other Total, other adverse events | 39 / 111 |
| serious Total, serious adverse events | 1 / 111 |
Outcome results
First go Insertion Success Rate
Whether insertion during first go was successful or not
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | First go Insertion Success Rate | 100 Participants |
First go Successful Ventilation Rate
Whether ventilation during first go was successful or not
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | First go Successful Ventilation Rate | 110 Participants |
Number of Participants With Complication Free Insertions
Number of participants with complication free insertions divided by total number of participants
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | Number of Participants With Complication Free Insertions | 72 Participants |
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Collect number of pre-defined complications of device usage. Secondary complication where asked about on Day 2 to ensure patients had recovered from the effects of the anaesthetic and are able to report any complications.
Time frame: Day 2
Population: Further breakdown of when complications occurred and the pre-defined complications of device usage are presented for the number of participants who experienced complications.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced complications | 13 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Vomiting | 1 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Sore throat | 10 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Pain on swallowing | 1 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Neck or mouth ache | 1 Participants |
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal
Collect number of pre-defined complications of device usage
Time frame: Day 1
Population: Further breakdown of when complications occurred and the pre-defined complications of device usage are presented for the number of participants who experienced complications.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced complications | 39 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced complications immediately following device insertion | 6 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced complications during maintenance of anaesthesia | 1 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced complications upon extubation | 32 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mucosal injury | 19 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild post-operative sore throat | 37 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild pain on swallowing | 12 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild post-operative dysphonia | 7 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild mouth pain | 3 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild jaw pain | 3 Participants |
| LMA Protector | Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal | Number who experienced mild numbness of tongue | 1 Participants |
Interventions Needed to Ensure Airway Patency
Collect number of predefined interventions needed to keep airway patent
Time frame: Day 1
Population: The number analysed in one or more rows relates to the number of participants for whom 1 or more airway manipulations was required.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| LMA Protector | Interventions Needed to Ensure Airway Patency | 1 or more airway manipulation required | 67 Participants |
| LMA Protector | Interventions Needed to Ensure Airway Patency | Manipulation: Jaw thrust | 50 Participants |
| LMA Protector | Interventions Needed to Ensure Airway Patency | Manipulation: Neck extension | 45 Participants |
| LMA Protector | Interventions Needed to Ensure Airway Patency | Manipulation: Chin lift | 4 Participants |
| LMA Protector | Interventions Needed to Ensure Airway Patency | Manipulation: Reposition device | 3 Participants |
Lowest Oxygen Saturation Level
Record of lowest oxygen saturation reading across all participants
Time frame: Day 1
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| LMA Protector | Lowest Oxygen Saturation Level | 91 Percent of oxygen saturation |
Number of Participants With Adequate Tidal Volume at Attempt of Ventilation
The success of ventilation will depend on whether there was tidal volume \> 7ml/kg
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | Number of Participants With Adequate Tidal Volume at Attempt of Ventilation | 110 Participants |
Number of Participants With Square Capnography Trace
The success of ventilation will depend on whether there was square capnography trace
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | Number of Participants With Square Capnography Trace | 110 Participants |
Number of Participants With Stable Oxygen Saturations
The success of ventilation will depend on whether there was stable SpO2
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | Number of Participants With Stable Oxygen Saturations | 110 Participants |
Number of Participants With Visible Chest Movement
The success of ventilation will depend on whether there was visible chest movement
Time frame: Day 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LMA Protector | Number of Participants With Visible Chest Movement | 110 Participants |
Time to First Square Capnography Waveform
Record time in seconds of time to first capnography trace
Time frame: Day 1
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| LMA Protector | Time to First Square Capnography Waveform | 31 Seconds |